Today is a big day for Moderna. The FDA is convening its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to debate the company’s mRNA-based seasonal flu shot, mFLUSIVA (mRNA-1010). The agency has an August 5 deadline to deliver an approval decision. That’s the kind of hard date that focuses attention.

Here’s the thing — the road to today was anything but smooth. Back in February, the FDA issued a rare refusal-to-file letter, rejecting Moderna’s initial biologics license application outright. Regulators flagged that the late-stage trial compared mRNA-1010 against a standard-dose flu vaccine rather than the high-dose or adjuvanted formulations now considered the best available standard of care for older adults. That was a gut punch. The stock got hit, and Moderna quietly shelved its prior 2028 breakeven guidance as a result.

Then, one week later, the FDA reversed course entirely. Accepted the revised filing. Set the August 5 target action date. Moderna exercised a Priority Review Voucher to accelerate the timeline.

So now here we are. The advisory committee meeting that is happening today is only the second such public hearing held in the past ten months — a signal of increasing transparency from the agency following months of closed-door decisions under the current administration. The panel vote is non-binding, but these meetings move stocks. Investors will be watching closely how committee members discuss the data on adults 50 and older, the specific group with the accelerated-approval label and a required follow-up study attached to it.

Slight tangent, but it matters: the flu vaccine alone represents a potential $1 billion revenue opportunity for Moderna, according to Jefferies. The company reported $389 million in Q1 2026 revenue — up 260% year-over-year and 55% above estimates, driven heavily by international sales, particularly the UK market. Full-year 2026 guidance is maintained at up to 10% revenue growth. That context is important. Moderna is not a broken story. It’s a company that’s been rebuilding its revenue base after COVID tailwinds faded, and the flu vaccine is a critical piece of that rebuild.

The other leg of the bull case is the cancer vaccine. Moderna and Merck recently presented five-year follow-up data for intismeran autogene (mRNA-4157) in combination with Keytruda. The data showed a 49% reduction in the risk of recurrence or death for high-risk melanoma patients. That’s not a preliminary read — that’s five years of durability data, and it has materially shifted how institutional investors are thinking about the mRNA platform beyond infectious disease.

Moderna has climbed over 120% from its 52-week low of $22.28 set in November 2025. The 52-week high sits at $59.55. Shares are currently trading in the low $50s heading into today’s panel. The stock has been rangebound recently, which makes the adcomm outcome the cleanest near-term catalyst on the board right now.

Whether the committee votes favorably or raises concerns, the reaction will be sharp. That’s the kind of binary event that either re-accelerates this move or gives it back in a session. Worth watching closely.

– WSM Editorial Desk